Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
September 14, 2020
- Komeito Prods Govt to Tap State Coffers for Coronavirus Vaccinations
September 11, 2020
- MHLW Calls for Smooth Supply of Flu Shots as It Anticipates Surging Demand
September 11, 2020
- Japan to Steadily Collect Info on AstraZeneca Trial Pause: Minister
September 11, 2020
- Japan to Require Pledges from Troubled Generic Makers to Skip Next Listing Round If Supply Issues Occur Again
September 10, 2020
- Label Revisions Ordered for Plaquenil, Relumina
September 10, 2020
- Japan Scrambles to Collect Info on AstraZeneca Vaccine Trial Pause, Sticks to 2021 H1 Immunization Goal
September 10, 2020
- MHLW Erases Hydroxychloroquine, 4 Other Drugs from COVID-19 Treatment Guide
September 10, 2020
- Bid-Rigging Scandal by Wholesalers “Interferes with” Development of Pharma Industry: MHLW Bureau Chief
September 9, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- 1st COVID-19 Case Confirmed at NIHS
September 9, 2020
- Coronavirus Vaccines “Will Need to Be Evaluated More Carefully than Ordinary Medicines”: Top MD Bureaucrat
September 8, 2020
- Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
September 8, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
- PMDA Reviewing Safety Risks for Takecab, 2 Other Drugs
September 7, 2020
- Former Pharma Bureau Chief Tarumi to Assume Vice Health Minister on September 14
September 7, 2020
- PMDA Presents Views on Efficacy, Safety Evaluations for Domestic Development of COVID-19 Vaccines
September 4, 2020
- Govt Holds 1st Meeting of Regenerative Medicine/Cell Therapy Panel, Eyeing Proposals in FY2021
September 4, 2020
- Will Temporary Measures in R&D Tax Credit System Be Extended? Enthusiasm for R&D Investment Could Determine Outcome
September 3, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…